相关实验视频

Updated: Jun 27, 2025

Computer-Aided Three-Dimensional Visualization in the Treatment of Locally Advanced Thyroid Cancer

Computer-Aided Three-Dimensional Visualization in the Treatment of Locally Advanced Thyroid Cancer

Published on: June 9, 2023

基于不同淋巴结分期系统的竞争性风险模型的应用和子组分析在差异化甲状腺癌中

Zhe Xu Cao¹, Jiang Sheng Huang¹, Ming Ming Wang²

¹Department of Thyroid Surgery, The Second Xiangya Hospital, Central South University, 139 Renmin Middle Road, Changsha City, Hunan Province, China.

Updates in surgery

|May 1, 2024

概括

阳性淋巴结数 (PLNNs) 提供了差异化甲状腺癌 (DTC) 的最佳预后值,特别是在N1阶段的疾病中. 13 PLNNs的最佳切断值可以改善患者管理和预后准确性.

科学领域:

内分泌学在内分泌学.
在瘤学瘤学.
医学统计医学统计

背景情况:

在全球范围内,差异化甲状腺癌 (DTC) 发病率正在上升,需要改进的预后工具.
准确的分期对于DTC中有效的患者管理至关重要.
现有的淋巴结分期系统需要对其在DTC的预后有效性进行评估.

研究的目的:

为了评估不同淋巴结分期系统在差异化甲状腺癌的预后价值.
为了比较阳性淋巴结数 (PLNNs),转移性淋巴结比率 (MLNR) 和DTC预后中阳性淋巴结 (LODDS) 的日志几率的疗效.
确定最适合DTC的淋巴结分期系统,特别是在N1阶段的疾病中.

主要方法:

使用了SEER数据库 (1998-2016) 拥有16527个DTC患者记录.
在单变量和多变量分析中采用竞争性风险模型.
评估N阶段,PLNN,MLNR,LODDS和LONT,包括子组和ROC分析.

主要成果:

不同的淋巴结分期系统显示出不同的预后相关性.
阳性淋巴结数 (PLNNs) 在多个亚组中显示出显著的预后相关性.
对于N1阶段的DTC,PLNNs被证明比LODDS和MLNR更适合,最佳切断值为13.

结论:

阳性淋巴结数 (PLNNs) 在差异化甲状腺癌中表现出最高的预后分辨疗效.
对于分期N1期DTC患者来说,PLNN特别有价值.
该研究确定了13 PLNNs的最佳切断值,提高了预后模型的实用性.

关键词:

竞争风险模型的竞争风险模型.有差异化的甲状腺癌.淋巴结分期系统是淋巴结分期系统.塞尔·塞尔 (Seer) 是一个看得见的人.小组分析小组分析小组分析

更多相关视频

Establishing a Competing Risk Regression Nomogram Model for Survival Data

Establishing a Competing Risk Regression Nomogram Model for Survival Data

Published on: October 23, 2020

Transoral Endoscopic Thyroidectomy Vestibular Approach for Thyroid Lobectomy

Transoral Endoscopic Thyroidectomy Vestibular Approach for Thyroid Lobectomy

Published on: May 12, 2023

相关概念视频

Comparing the Survival Analysis of Two or More Groups

Comparing the Survival Analysis of Two or More Groups

Survival analysis is a cornerstone of medical research, used to evaluate the time until an event of interest occurs, such as death, disease recurrence, or recovery. Unlike standard statistical methods, survival analysis is particularly adept at handling censored data—instances where the event has not occurred for some participants by the end of the study or remains unobserved. To address these unique challenges, specialized techniques like the Kaplan-Meier estimator, log-rank test, and...

Cancer Survival Analysis

Cancer Survival Analysis

Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...